Axim Biotechnologies Inc Financials
This page shows Axim Biotechnologies Inc (AXIM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2023 annual data. Scores normalized against common benchmarks. How we calculate these scores
Axim Biotechnologies Inc has an operating margin of -6961.0%, meaning the company retains $-6961 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -52425.6% the prior year.
Axim Biotechnologies Inc's revenue surged 345.3% year-over-year to $40K, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Axim Biotechnologies Inc's current ratio of 0.03 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Axim Biotechnologies Inc generated -$1.0M in operating cash flow, capex of $0 consumed most of it, leaving -$1.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Axim Biotechnologies Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Axim Biotechnologies Inc generates $0.13 in operating cash flow (-$1.0M OCF vs -$8.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Axim Biotechnologies Inc earns $-19.6 in operating income for every $1 of interest expense (-$2.8M vs $140K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Axim Biotechnologies Inc generated $40K in revenue in fiscal year 2023. This represents an increase of 345.3% from the prior year.
Axim Biotechnologies Inc's EBITDA was -$2.3M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.0% from the prior year.
Axim Biotechnologies Inc reported -$8.1M in net income in fiscal year 2023. This represents a decrease of 29.1% from the prior year.
Axim Biotechnologies Inc earned $-0.04 per diluted share (EPS) in fiscal year 2023. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Axim Biotechnologies Inc generated -$1.0M in free cash flow in fiscal year 2023, representing cash available after capex. This represents an increase of 49.8% from the prior year.
Axim Biotechnologies Inc held $156K in cash against $4.9M in long-term debt as of fiscal year 2023.
Axim Biotechnologies Inc had 246M shares outstanding in fiscal year 2023. This represents an increase of 27.8% from the prior year.
Margins & Returns
Axim Biotechnologies Inc's operating margin was -6961.0% in fiscal year 2023, reflecting core business profitability. This is up 45464.6 percentage points from the prior year.
Axim Biotechnologies Inc's net profit margin was -20395.0% in fiscal year 2023, showing the share of revenue converted to profit. This is up 49948.1 percentage points from the prior year.
Capital Allocation
Axim Biotechnologies Inc invested $125K in research and development in fiscal year 2023. This represents a decrease of 18.3% from the prior year.
Axim Biotechnologies Inc invested $0 in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
AXIM Income Statement
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17K-67.0% | $53K+320.1% | $13K+31.6% | $10K-3.5% | $10K+34.2% | $7K | N/A | $1K |
| Cost of Revenue | $2K | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Gross Profit | $16K | N/A | N/A | N/A | $10K | N/A | N/A | $1K |
| R&D Expenses | $4K-73.8% | $15K-57.4% | $36K+4.8% | $35K+1.9% | $34K+67.6% | $20K | N/A | $30K |
| SG&A Expenses | $473K+42.9% | $331K-46.9% | $623K+36.5% | $457K-19.4% | $567K-4.1% | $591K | N/A | $1.2M |
| Operating Income | -$569K-41.8% | -$402K+46.7% | -$754K-28.1% | -$589K+15.6% | -$698K+1.8% | -$711K | N/A | -$1.3M |
| Interest Expense | $178K+209.0% | -$164K+73.5% | -$618K-1056.3% | $65K-91.4% | $752K+1399.3% | -$58K | N/A | $57K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | N/A | $0 |
| Net Income | -$2.3M-676.5% | -$292K+84.6% | -$1.9M-679.1% | $328K+108.8% | -$3.7M-34.8% | -$2.8M | N/A | -$2.0M |
| EPS (Diluted) | $-0.01-900.0% | $-0.00 | N/A | $0.00+103.5% | $-0.02-53.8% | $-0.01 | N/A | $-0.01 |
AXIM Balance Sheet
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.7M-5.3% | $3.9M-4.5% | $4.1M+1.9% | $4.0M-4.8% | $4.2M+5.0% | $4.0M-4.0% | $4.2M-6.0% | $4.5M |
| Current Assets | $20K-79.1% | $97K-38.2% | $156K+573.8% | $23K-76.2% | $97K+72.4% | $57K-45.6% | $104K-58.3% | $249K |
| Cash & Equivalents | $6K-93.8% | $97K-38.2% | $156K+573.8% | $23K-76.2% | $97K+82.1% | $54K+13.2% | $47K-71.1% | $164K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $20K |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.3M+16.5% | $11.4M-3.4% | $11.8M+17.8% | $10.0M-28.6% | $14.0M+37.2% | $10.2M+12.9% | $9.0M+2.0% | $8.9M |
| Current Liabilities | $6.6M+36.8% | $4.8M-19.7% | $6.0M+39.7% | $4.3M-48.9% | $8.4M+72.0% | $4.9M+43.4% | $3.4M+7.2% | $3.2M |
| Long-Term Debt | $6.0M+4954.6% | $118K-97.6% | $4.9M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$9.5M-28.0% | -$7.4M+2.7% | -$7.7M-28.6% | -$6.0M+38.9% | -$9.8M-58.3% | -$6.2M-27.7% | -$4.8M-10.2% | -$4.4M |
| Retained Earnings | -$74.7M-3.1% | -$72.5M-0.4% | -$72.2M-2.7% | -$70.3M+0.5% | -$70.6M-5.6% | -$66.9M-4.3% | -$64.1M-1.4% | -$63.2M |
AXIM Cash Flow Statement
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$262K-3.6% | -$253K-1391.2% | $20K+107.4% | -$265K+58.9% | -$644K-353.4% | -$142K+55.0% | -$316K+1.8% | -$321K |
| Capital Expenditures | N/A | $3K | $0 | N/A | N/A | N/A | $0-100.0% | $3K |
| Free Cash Flow | N/A | -$255K-1405.7% | $20K | N/A | N/A | N/A | -$316K+2.6% | -$324K |
| Investing Cash Flow | $0+100.0% | -$3K | $0 | $0 | $0 | $0 | $0+100.0% | -$3K |
| Financing Cash Flow | $171K-12.6% | $196K+72.1% | $114K-40.2% | $190K-72.3% | $688K+363.9% | $148K-25.5% | $199K-52.9% | $423K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AXIM Financial Ratios
| Metric | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.0% | N/A | N/A | N/A | 100.0% | N/A | N/A | 100.0% |
| Operating Margin | -3257.9%-2499.9pp | -758.0%+5220.5pp | -5978.4%+164.3pp | -6142.7%+884.4pp | -7027.2%+2579.9pp | -9607.1% | N/A | -100298.3% |
| Net Margin | -12985.9%-12434.2pp | -551.7%+14532.2pp | -15083.9%-18512.2pp | 3428.3%+40927.5pp | -37499.2%-151.2pp | -37347.9% | N/A | -154836.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -60.9%-53.5pp | -7.4%+38.7pp | -46.2%-54.3pp | 8.1%+95.8pp | -87.7%-19.4pp | -68.3% | N/A | -45.4% |
| Current Ratio | 0.00-0.0 | 0.020.0 | 0.03+0.0 | 0.010.0 | 0.010.0 | 0.01-0.0 | 0.03-0.0 | 0.08 |
| Debt-to-Equity | -0.63-0.6 | -0.02+0.6 | -0.64+1.0 | -1.68-0.2 | -1.44+0.2 | -1.66+0.2 | -1.87+0.1 | -2.02 |
| FCF Margin | N/A | -482.0%-637.0pp | 155.1% | N/A | N/A | N/A | N/A | -24652.6% |
Note: Shareholder equity is negative (-$7.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Axim Biotechnologies Inc's annual revenue?
Axim Biotechnologies Inc (AXIM) reported $40K in total revenue for fiscal year 2023. This represents a 345.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Axim Biotechnologies Inc's revenue growing?
Axim Biotechnologies Inc (AXIM) revenue grew by 345.3% year-over-year, from $9K to $40K in fiscal year 2023.
Is Axim Biotechnologies Inc profitable?
No, Axim Biotechnologies Inc (AXIM) reported a net income of -$8.1M in fiscal year 2023, with a net profit margin of -20395.0%.
What is Axim Biotechnologies Inc's EBITDA?
Axim Biotechnologies Inc (AXIM) had EBITDA of -$2.3M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Axim Biotechnologies Inc have?
As of fiscal year 2023, Axim Biotechnologies Inc (AXIM) had $156K in cash and equivalents against $4.9M in long-term debt.
What is Axim Biotechnologies Inc's operating margin?
Axim Biotechnologies Inc (AXIM) had an operating margin of -6961.0% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Axim Biotechnologies Inc's net profit margin?
Axim Biotechnologies Inc (AXIM) had a net profit margin of -20395.0% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Axim Biotechnologies Inc's free cash flow?
Axim Biotechnologies Inc (AXIM) generated -$1.0M in free cash flow during fiscal year 2023. This represents a 49.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Axim Biotechnologies Inc's operating cash flow?
Axim Biotechnologies Inc (AXIM) generated -$1.0M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Axim Biotechnologies Inc's total assets?
Axim Biotechnologies Inc (AXIM) had $4.1M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Axim Biotechnologies Inc's capital expenditures?
Axim Biotechnologies Inc (AXIM) invested $0 in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Axim Biotechnologies Inc spend on research and development?
Axim Biotechnologies Inc (AXIM) invested $125K in research and development during fiscal year 2023.
What is Axim Biotechnologies Inc's current ratio?
Axim Biotechnologies Inc (AXIM) had a current ratio of 0.03 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Axim Biotechnologies Inc's debt-to-equity ratio?
Axim Biotechnologies Inc (AXIM) had a debt-to-equity ratio of -0.64 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Axim Biotechnologies Inc's return on assets (ROA)?
Axim Biotechnologies Inc (AXIM) had a return on assets of -195.6% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Axim Biotechnologies Inc's cash runway?
Based on fiscal year 2023 data, Axim Biotechnologies Inc (AXIM) had $156K in cash against an annual operating cash burn of $1.0M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Axim Biotechnologies Inc's debt-to-equity ratio negative or unusual?
Axim Biotechnologies Inc (AXIM) has negative shareholder equity of -$7.7M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Axim Biotechnologies Inc's Piotroski F-Score?
Axim Biotechnologies Inc (AXIM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Axim Biotechnologies Inc's earnings high quality?
Axim Biotechnologies Inc (AXIM) has an earnings quality ratio of 0.13x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Axim Biotechnologies Inc cover its interest payments?
Axim Biotechnologies Inc (AXIM) has an interest coverage ratio of -19.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Axim Biotechnologies Inc?
Axim Biotechnologies Inc (AXIM) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.